Shares of Nuvalent NUVL have soared nearly 20% in the past week owing to encouraging updates on its two investigational ...

Biotech Nuvalent unveiled updates on two experimental cancer medicines over the weekend. Analysts say each could be the best ...

Nuvalent achieved positive data from the phase 1/2 ALKOVE-1 study using NVL-655 for the treatment of patients with ALK-mutant ...

Nuvalent shows promise with strong clinical data for zidesamtinib and NVL-655 in treating ROS1- and ALK-positive NSCLC. Read ...

Nuvalent, Inc. (NUVL), a company focused on cancer treatment, announced on Monday that it has commenced an underwritten public ...

Scattered investor qualms about Nuvalent Inc.’s largely upbeat data during the European Society for Medical Oncology (ESMO) ...

We recently compiled a list of the 10 Largest Biotech Hedge Funds and Their Top Stock Picks. In this article, we are going to ...

Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the pricing ...

Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Nuvalent (NUVL – Research Report). The associated price target ...

Nuvalent Inc. followed positive data during the European Society for Medical Oncology (ESMO) meeting with an upsized $500 million public offering. The Cambridge, Mass.-based firm is selling 5 million ...

Shares of Nuvalent rose after the company offered promising updates about the progress of its parallel lead cancer drug programs through clinical trials. The stock was up 20% at $105 in premarket ...

In terms of valuation, Nuvalent Inc’s market capitalization stands at $7.27 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value.